- Home
- ABUS vs DGICA Comparison
ABUS vs DGICA Comparison
Compare ABUS & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- DGICA
- Stock Information
- Founded
- ABUS 2005
- DGICA 1986
- Country
- ABUS United States
- DGICA United States
- Employees
- ABUS N/A
- DGICA N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- DGICA Property-Casualty Insurers
- Sector
- ABUS Health Care
- DGICA Finance
- Exchange
- ABUS Nasdaq
- DGICA Nasdaq
- Market Cap
- ABUS 711.2M
- DGICA 705.0M
- IPO Year
- ABUS N/A
- DGICA N/A
- Fundamental
- Price
- ABUS $4.46
- DGICA $19.15
- Analyst Decision
- ABUS Strong Buy
- DGICA Hold
- Analyst Count
- ABUS 2
- DGICA 1
- Target Price
- ABUS $5.00
- DGICA $18.00
- AVG Volume (30 Days)
- ABUS 930.7K
- DGICA 121.0K
- Earning Date
- ABUS 11-10-2025
- DGICA 10-30-2025
- Dividend Yield
- ABUS N/A
- DGICA 3.82%
- EPS Growth
- ABUS N/A
- DGICA 965.80
- EPS
- ABUS N/A
- DGICA 2.34
- Revenue
- ABUS $15,416,000.00
- DGICA $993,644,532.00
- Revenue This Year
- ABUS $138.02
- DGICA $2.26
- Revenue Next Year
- ABUS N/A
- DGICA $3.46
- P/E Ratio
- ABUS N/A
- DGICA $8.15
- Revenue Growth
- ABUS 53.23
- DGICA 3.36
- 52 Week Low
- ABUS $2.71
- DGICA $14.17
- 52 Week High
- ABUS $5.10
- DGICA $21.12
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- DGICA 49.64
- Support Level
- ABUS $4.26
- DGICA $19.09
- Resistance Level
- ABUS $4.61
- DGICA $19.49
- Average True Range (ATR)
- ABUS 0.20
- DGICA 0.39
- MACD
- ABUS -0.01
- DGICA -0.04
- Stochastic Oscillator
- ABUS 65.45
- DGICA 43.42
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.